Frontlight ResearchEarly access
Taking people in South KoreaNo phase
Studies real-world safety of ozanimod in people with ulcerative colitis
Observes safety of ozanimod in adults with moderate to severe ulcerative colitis.
Key facts
- Who runs it
- Bristol-Myers Squibb
- Where
- Seoul, South KoreaSee the site
- Trial code
- Registry title
- A Post-Marketing Surveillance Study to Assess Safety of Ozanimod in Patients With Moderate to Severe Active UC in Korea
- Status
- Recruiting
- People taking part
- 3,000 people, planned
- Started
- 19 Apr 2024
- Expected to end
- 1 Apr 2028
- Type of study
- Observational
- Treatments tested
- Ozanimod
- Record updated
- 22 August 2024
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The study is looking for adults in Korea with moderate to severe active ulcerative colitis who will receive ozanimod as approved on its label. It checks how safe the drug is in everyday use.
- Age
- 19 years or older
- Sex
- All sexes can join.
- Disease stage
- Moderate to severe active ulcerative colitis
Main reasons for not taking part
- Prescribed ozanimod for a use that is not approved in Korea
- Ozanimod is contraindicated according to the Korean prescribing information approved by the Ministry of Food and Drug Safety
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Adult participants 19 years of age or older
- Participants who will receive ozanimod according to the approved label after enrollment
- Participants who sign the informed consent form voluntarily
Who cannot take part
- Participants for whom ozanimod is contraindicated as clarified in Korean prescribing information approved by Ministry of Food and Drug Safety
- Participants who are prescribed ozanimod for therapeutic indications not approved in Korea
Where in South Korea
- Bristol-Myers Squibb YHSeoul, South KoreaContact: Hyunho KimTaking people
About the trial
What the trial wants to find out
The purpose of this observational study is to assess the real-world safety of ozanimod in Korean participants with moderate to severe active ulcerative colitis.
The group in the trial
- Participants with moderate to severe active ulcerative colitis treated with ozanimod
Treatment: Ozanimod
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Post-Marketing Surveillance (PMS) Study on Zeposia® (Ozanimod) Use Among Moderate to Severe Active Ulcerative Colitis Patients in Korea
- Plain-language title
- Studies real-world safety of ozanimod in people with ulcerative colitisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 22 August 2024